X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-america-presents-positive-results-from-pivotal-phase-3-boundless-trial-of-investigational-nd0612-in-people-with-parkinsons-disease-experiencing-motor-fluctuations-301911810.html
https://health.economictimes.indiatimes.com/news/pharma/us-fda-declines-to-approve-abbvies-parkinsons-disease-therapy/98931024
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-8-2023-15780.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216537
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216505
https://www.clinicaltrialsarena.com/news/cerevance-outlines-parkinsons-disease-tri/
https://www.prnewswire.com/news-releases/beyond-phase-2b-data-indicates-nd0612-has-a-positive-long-term-safety-profile-for-people-with-parkinsons-disease-301516232.html
https://www.prnewswire.com/news-releases/avion-pharmaceuticals-llc-an-alora-pharmaceuticals-company-announces-the-fda-approval-and-availability-of-dhivytm-for-the-treatment-of-parkinsons-disease-301481295.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213212
https://www.biospace.com/article/releases/acorda-therapeutics-announces-agreement-to-commercialize-inbrija-in-germany/?s=71
https://www.biospace.com/article/abbvie-eyes-potential-approval-of-parkinson-s-disease-treatment-following-positive-phase-iii-results/?s=71
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214091
http://www.pharmafile.com/news/587415/amneal-s-ipx-203-shows-promising-results-motor-fluctuations-parkinson-s-disease
https://endpts.com/amneal-touts-results-from-phase-iii-trial-on-parkinsons-novarock-partners-on-cancer-drug/
https://www.businesswire.com/news/home/20210616005216/en/Acorda-Therapeutics-Announces-Repayment-of-Convertible-Senior-Notes
https://www.businesswire.com/news/home/20210608005644/en/Bayer-to-Advance-Two-First-of-its-Kind-Investigational-Cell-and-Gene-Therapies-for-Parkinson%E2%80%99s-Disease
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214092
https://www.biospectrumasia.com/news/26/16752/singapore-develops-single-daily-pill-for-parkinsons-disease.html
https://www.prnewswire.com/news-releases/abbvie-to-present-new-data-from-18-abstracts-at-the-international-congress-of-parkinsons-disease-and-movement-disorders-301128096.html
https://www.sciencedaily.com/releases/2020/09/200910120118.htm#:~:text=09%2F200910120118.htm-,Investigators%20have%20determined%20that%20treating%20patients%20with%20an%20advanced%20form,stabilized%20and%20improved%20their%20vision.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203424
https://www.fiercepharma.com/pharma/acorda-backs-way-off-800m-estimate-inbrija-after-lackluster-year
https://www.prnewswire.com/news-releases/kyowa-kirin-announces-marketing-authorisation-application-for-istradefylline-validated-by-european-medicines-agency-300981075.html
https://www.biospectrumasia.com/news/25/14786/lobsor-pharma-receives-japanese-patent-for-apd-solution.html
https://www.prnewswire.com/news-releases/mitsubishi-tanabe-pharma-corporation-group-announces-presentation-of-patient-reported-results-from-phase-2-nd0612-study-at-international-congress-of-parkinsons-disease-and-movement-disorders-300923267.html
https://www.ema.europa.eu/en/documents/overview/inbrija-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma-asia/fiercepharmaasia-hifibio-s-kite-backed-c-round-kyowa-kirin-s-parkinson-s-nod-relief-for
https://www.fda.gov/drugs/drug-safety-and-availability/fda-review-finds-no-increased-risk-prostate-cancer-parkinsons-disease-medicines-containing
https://www.fiercebiotech.com/biotech/intec-flunks-phase-3-parkinson-s-test-against-merck-drug
https://www.fiercebiotech.com/biotech/modag-raises-a-round-to-test-disease-modifying-parkinsonian-drug?utm_source=internal&utm_medium=rss
https://www.biospace.com/article/releases/intec-pharma-announces-results-from-earlier-phase-2-clinical-trial-of-accordion-pill-carbidopa-levodopa-in-advanced-parkinson-s-disease-patients-published-in-parkinsonism-and-related-disorders/
https://www.fiercepharma.com/pharma-asia/foreign-drugmakers-under-threat-as-china-rolls-out-drug-list-to-boost-generic
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-gets-usfda-nod-for-parkinsons-disease-treatment-drugs/articleshow/69673175.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210341
https://www.businesswire.com/news/home/20190117005694/en/Acorda-Announces-Lancet-Neurology-Publication-Phase-3
https://www.businesswire.com/news/home/20181221005620/en/ADDING-MULTIMEDIA-Acorda-Therapeutics-Announces-FDA-Approval
https://www.fiercepharma.com/pharma/battered-acorda-pulls-off-delayed-parkinson-s-approval-for-inbrija
https://endpts.com/acorda-celebrates-an-fda-ok-so-does-that-make-them-a-takeover-target/
https://www.reuters.com/article/us-intec-pharma-ceo/israels-intec-pharma-eyes-revenue-from-parkinsons-drug-in-2019-idUSKCN1NC236
https://www.fiercepharma.com/manufacturing/merck-runs-out-parkinson-s-disease-drug-sinemet-as-manufacturing-issues-unexpected
https://www.fiercebiotech.com/medtech/fda-sets-back-review-date-acorda-s-levodopa-inhaler-for-parkinson-s-disease?mkt_tok=eyJpIjoiTm1SbE5tVTRZalkyTURrMyIsInQiOiJyZVFCQ1c0aVY3eWRVcG1oYzQybVh4T3BXVVJtM2tuQmJ5VjhtZkF5ZVo0Q0syTGR6RzRwXC9RWVBDOWx5ekdBMzVDMmpHbVdSQk5iSFZXVXpWVTR5cU94dmVscThpQk9ia1R1NDlEeEJGcnZsVFhFM01QalU3TVZ3MWtSUFhuYlcifQ%3D%3D&mrkid=67302085
https://endpts.com/acordas-awful-no-good-just-plain-bad-week-gets-worse-as-fda-hands-execs-another-delay-on-inbrija-battered-shares-tumble-again/?utm_medium=email&utm_campaign=564%20Thu%2091318%20Genentech%20science%20crew%20spotlights%20a%20breakthrough%20SEC%20alleges%20hedge%20fund%20player%20lied%20in%20biotech%20short%20attack&utm_content=564%20Thu%2091318%20Genentech%20science%20crew%20spotlights%20a%20breakthrough%20SEC%20alleges%20hedge%20fund%20player%20lied%20in%20biotech%20short%20attack+CID_c4f98919d8f5ac4097aa265dd3bfc0c5&utm_source=ENDPOINTS%20emails&utm_term=Acordas%20awful%20no%20good%20just%20plain%20bad%20week%20gets%20worse%20as%20FDA%20hands%20execs%20another%20delay%20on%20Inbrija%20%20battered%20shares%20tumble%20again
https://www.cnbc.com/2018/09/10/reuters-america-update-1-u-s-appeals-court-invalidates-acorda-patents-on-ms-drug.html
Market Place
Share 
